A nonprofit research organization that develops vaccines and antibodies for HIV, tuberculosis, and emerging infectious diseases will be relocating to the Hudson County waterfront as IAVI is the latest business coming to Jersey City.
IAVI, formerly known as the International AIDS Vaccine Initiative, will be setting up shop in 29,782 square feet of space at 95 Greene Street. The property, which was modernized and redesigned several years ago, sits a block from the Hudson River in Exchange Place.
The nonprofit biotech will relocate its Vaccine Design and Development Lab from the Brooklyn Army Terminal. IAVI is represented regionally by a CBRE team of John Isaacs, Joseph DeRosa, Conor Dolan, and others.
“The Design and Development Lab team looks forward to joining the vibrant life sciences community at 95 Greene Street,” said Christopher L. Parks, Ph.D., Associate Vice President of Viral Vaccines and Head of the IAVI DDL. “This upgraded, fit-for-purpose lab space is tailored to the DDL’s unique infrastructure needs as a leader in vaccine R&D and in global health research.”
“We are poised to strengthen connections and accelerate progress with partners across the New York and New Jersey life sciences communities with our new footprint in Jersey City,” Parks added.
The IAVI Design and Development Lab is one of the world’s leading vaccine research and development labs and serves as the preclinical development hub for IAVI’s EID vaccine portfolio. Using the same vaccine vector as a licensed Ebola vaccine, DDL scientists design novel vaccine concepts for priority pathogens including Ebola Sudan, Marburg, Lassa, and COVID-19.
IAVI is a nonprofit scientific research organization dedicated to addressing global unmet health challenges. Its mission is to translate scientific discoveries into affordable, globally accessible public health solutions.
